Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01610830|
Recruitment Status : Unknown
Verified July 2012 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : June 4, 2012
Last Update Posted : April 23, 2014
Henoch Schonlein Purpura (HSP), vasculitis of small vessels with deposits of IgA, is considered by many authors as the systemic form of Berger's disease (IgA-N). IgA-N is characterized by IgA1 deposits in mesangial areas associated with mesangial proliferation. These two diseases remain the leading cause of ESRD by primitive glomerulopathy in Western countries. In recent years, considerable progress has been made in understanding the pathophysiological mechanisms of IgA-N. However, only a high rate of proteinuria at one year or the presence of severe glomerular inflammation on renal biopsy remain predictors of long term renal function. Moreover, the high variability of HSP clinical expression, from few purpura skin lesions that evolve favourably spontaneously, to rapidly progressive renal failure, remains so far unexplained but suggests the existence of individual genetic susceptibility.
In the first part of the study, we will study key factors based on physiopathological data obtained by our laboratory as well as by other groups. The second part of the study concerns genetic factors. Although the candidate genes that may confer a particular susceptibility to the disease, to progress to ESRD or respond to treatment are many, the genes involved in inflammation or controlling renin-angiotensin system are of particular interest.
We will apply these results by studying patients with HSP showing three distinct phenotypes (HSP with isolated cutaneous purpura or associated with minimal or severe renal disease) at diagnosis and after clinical remission.
The purpose of this study is to assess whether the phenotype at diagnosis is associated with the physiological markers and if one of them predicts a pejorative evolution of renal disease at 1 year. Meanwhile, study of polymorphism of selected genes of interest could allow identification of patients with specific genetic susceptibility or with bad prognosis factors who would be thus eligible for specific treatment.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||July 2014|
have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:
- Renal prognosis [ Time Frame: one time measure after a four hour writing session ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01610830
|Contact: Evangeline Pillebout, MD PhDemail@example.com|
|Contact: Renato Monteiro, MD PhD||33157277751||Renato.Monteiro@bichat.inserm.fr|
|Nephrology Unit - Hôpital St Louis||Recruiting|
|Paris, France, 75010|
|Contact: Evangeline Pillebout, MD PhD 33142499631 firstname.lastname@example.org|
|Contact: Renato Monteiro, MD PhD 33157277751 Renato.Monteiro@bichat.inserm.fr|
|Principal Investigator: Evangeline Pillebout, MDPhD|
|Principal Investigator:||Evangeline Pillebout, Md PhD||APHP - Hôpital St Louis - Paris 10 - France|